Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis-Reference-Cited by-同舟云学术

Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis

Published:2020-03-27 Issue:6485 Volume:367 Page:1468-1473
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Ebright Richard Y.¹^ORCID,Lee Sooncheol¹,Wittner Ben S.¹^ORCID,Niederhoffer Kira L.¹^ORCID,Nicholson Benjamin T.¹,Bardia Aditya¹²,Truesdell Samuel¹,Wiley Devon F.¹^ORCID,Wesley Benjamin¹,Li Selena¹^ORCID,Mai Andy¹^ORCID,Aceto Nicola¹,Vincent-Jordan Nicole¹,Szabolcs Annamaria¹^ORCID,Chirn Brian¹,Kreuzer Johannes¹^ORCID,Comaills Valentine¹^ORCID,Kalinich Mark¹^ORCID,Haas Wilhelm¹²^ORCID,Ting David T.¹²^ORCID,Toner Mehmet³⁴⁵,Vasudevan Shobha¹²^ORCID,Haber Daniel A.¹²⁶^ORCID,Maheswaran Shyamala¹⁵^ORCID,Micalizzi Douglas S.¹²^ORCID

Affiliation:

1. Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.

2. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

3. Center for Bioengineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

4. Shriners Hospital for Children, Boston, MA 02114, USA.

5. Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

6. Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02114, USA.

Abstract

Metastasis: A matter of translation? Solid tumors shed a small number of cancer cells into the bloodstream, some of which are believed to contribute to metastasis. The molecular features that confer these circulating tumor cells (CTCs) with metastatic potential are poorly understood. Ebright et al. studied CTCs from breast cancer patients and found that cells with increased expression levels of certain ribosomal proteins and regulators of translation had greater metastatic capacity in a mouse model (see the Perspective by Ma and Jeffrey). Consistent with this finding, patients with higher levels of this subset of CTCs tended to have a poorer prognosis. Science , this issue p. 1468 ; see also p. 1424

Funder

National Institutes of Health

National Cancer Institute

Susan G. Komen

National Institute of General Medical Sciences

Howard Hughes Medical Institute

Breast Cancer Research Foundation

National Foundation for Cancer Research

American Society of Clinical Oncology

American Cancer Society

Publisher

American Association for the Advancement of Science (AAAS)